Smart people learn from their own mistakes. Wise people learn from the mistakes of others. Thanks for increasing my wisdom. I'm here for the long term.
Medical docs aren't looking for a cure, IMO. Alziheimers is a cash cow for their business. I hope, for the sake of the victims of Alzheimers, that a cure is on the horizon.
Either folks believe in the science or they don't. Seems some don't. Maybe they shouldn't invest here. I'm in at 27 cents and have no intention of selling anytime soon. So, I guess you could say I believe in the science. All indications look like this probably stops and possibly reverses Alzheimer's Disease. There's always a risk but I think McFarlane's enthusiasm is coming from the results he sees and not a p&d. Just my opinion.
Hello Peter. I plan to hold for at least a year so my capital gains tax will be around 15% instead of close to 30%. In addition to that, I believe in the science and realize the sky is the limit on this investment. This stock is way underpriced right now. It is hard to put a value on it because there are a lot of drugs in its pipeline. These are drugs that could potentially be worth billions of dollars. Our management team is top notch. The folks we have on board wouldn't be there if they didn't believe in the science. Congratulations on finding this gem in your early investing career
"The MJFF grant is expected to fully fund a preclinical study on the effect of ANAVEX 2-73 in a Parkinson’s disease animal model, which seeks to provide a solid dataset that will justify moving forward to clinical development in Parkinson’s. "
Nice try anny
This stock is a Buy and Hold now. A simple math equasion: the less shares available for sale, the higher the price. I think it's called supply and demand.
Agreed 100%. Wait until AVXL reaches $20.00 then we'll talk. Don't forget the Epilepsy indication and several others.
New York — January 12, 2015
Anavex Doses First Alzheimer’s Patient in Phase 2a Trial of ANAVEX 2-73 and ANAVEX PLUS
The first part (PART A) is a simple randomized, open-label, two-period, cross-over, adaptive trial lasting up to 36 days. The primary objective of Part A is to evaluate the maximum tolerated dose of ANAVEX 2-73 in these patients.
The second part (PART B) is an open-label extension in Phase 2a adaptive clinical trial of ANAVEX 2-73 and ANAVEX PLUS. At least 32 mild to moderate Alzheimer’s patients will be enrolled and they will be able to receive the study drug for up to 26 weeks to establish a longer drug effect to evaluate dose response, bioavailability, cognitive efficacy and the relationship of ANAVEX 2-73 as an add-on therapy to donepezil, the current standard of care.
Leadership has changed since 2006:
Our Pipeline is quite robust:
And here’s a list of potential indications for our future clinical trials:
Here’s a few words from our CEO:
My thought is that it will be you running away with your tail tucked. I'm quite confident that Pfizer or another deep pocketed pharaceutical company will step in to be part of what AVXL has in its pipeline. Stay tuned.
This explains it a bit better:
Anavex to Present Initial Clinical Data From the Phase 2a Clinical Trial of ANAVEX 2-73 at the Alzheimer’s Association International Conference (AAIC)
June 30, 2015 07:47
H2 is less than a month away. Investigational New Drug application to be filed in the second half of the year.
Doing their own due dilligence before making any investments is on potential investors to weigh their own risk reward senerio. I find the rewards of investing here to far outweigh the risk at this share price. But then again, that's me. I'm totally in now and don't lose any sleep over this investment. I like the fact that their strategy is to attack this disease upstream and to combine with another drug to repair some of the damage that has already been done.
“ANAVEX 2-73 was recognized by the independent publication Alzheimer's Weekly as "The number one most promising drug in Alzheimer's Disease" after their analysis of more than 100 trials that treat dementias and following the review of more than 10,000 articles.”
I understand the skepticism here. That goes with the territory when trading is on the pink sheets. But I think the skeptisim with this company is unwarranted. In my opinion, this company should be trading on a higher exchange. The science justifies a higher exchange but that's not how it works. We are so far ahead of the curve when it comes to finding a cure for AD and effective treatment for many other neurological diseases. We are looking for partnerships to provide the money needed to advance to more clinical trials. But until that time, if/when the warrants are exercised, I think that will provide the money to keep us going. Our CEO not only has a PhD in science but also an MBA. He was CFO of two other biotech companies, so I think he is the right guy to lead this company. This stock is a definite buy and hold; too risky to trade with all the possible announcements that I expect to be forthcoming in the immediate future. As always, do your own DD. There may be traders here making a few bucks, but in my opinion, they will miss the big payday. Just my opinion.